A randomized, phase II study of preoperative plus postoperative Imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

Annals of Surgical Oncology

Volumn 16, Issue 4, 2009, Pages 910-919

  McAuliffe, John C ^a   Hunt, Kelly K ^a   Lazar, Alexander J F ^a   Choi, Haesun ^a   Qiao, Wei ^a   Thall, Peter ^a   Pollock, Raphael E ^a   Benjamin, Robert S ^a   Trent, Jonathan C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB;

ADULT; ANEMIA; ANOREXIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; MALE; MEMORY DISORDER; MORBIDITY; NAUSEA; NICK END LABELING; PELVIS ABSCESS; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; TREATMENT RESPONSE; TUMOR VOLUME; VAGINA BLEEDING; VOMITING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION;

EID: 62149141753     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0177-7     Document Type: Article

References (30)

1. DM Steinert JC McAuliffe JC Trent 2005 Imatinib mesylate in the treatment of gastrointestinal stromal tumour Expert Opin Pharmacother 6 105 13
2. LG Kindblom HE Remotti F Aldenborg JM Meis-Kindblom 1998 Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal Am J Pathol 152 1259 69
3. S Hirota K Isozaki Y Moriyama 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 80
4. MC Heinrich CL Corless A Duensing 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 10
5. R Capdeville E Buchdunger J Zimmermann A Matter 2002 Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat Rev Drug Discov 1 493 502
6. J Verweij PG Casali J Zalcberg 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 34
7. CD Blanke C Rankin GD Demetri 2008 Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 626 32
8. RP DeMatteo JJ Lewis D Leung 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 8
9. PJ Roberts B Eisenberg 2002 Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease Eur J Cancer 38 S37 8
10. CD Blanke BL Eisenberg MC Heinrich 2001 Gastrointestinal stromal tumors Curr Treat Options Oncol 2 485 91
11. TM Pawlik JN Vauthey EK Abdalla 2006 Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver Arch Surg 141 537 43 discussion 543-4
12. EH Ng RE Pollock MM Romsdahl 1992 Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas Cancer 69 1334 41
13. NCI Na. Common Terminology Criteria For Adverse Events. In: Cancer Therapy Evaluation Program, Edition DCTD, NCI, NIG, DHHS 2003.
14. S Singer BP Rubin ML Lux 2002 Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol 20 3898 905
15. JC Trent L Ramdas J Dupart 2006 Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor Cancer 107 1898 908
16. Therneau T, Grambsch P. Modeling survival data. New York: Springer; 2000.
17. E Kaplan P Meier 1958 Nonparametric estimator from incomplete observations J Am Stat Assoc 53 457 81
18. Snedecor G, Cochran W. Statistical methods. Iowa State: University Press; 1980.
19. GD Demetri M von Mehren CD Blanke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 80
20. M Debiec-Rychter R Sciot A Le Cesne 2006 KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 1093 103
21. M Bidri S Ktorza I Vouldoukis 1997 Nitric oxide pathway is induced by Fc epsilon RI and up-regulated by stem cell factor in mouse mast cells Eur J Immunol 27 2907 13
22. G Van Buren 2nd ER Camp AD Yang 2006 The role of nitric oxide in mediating tumour blood flow Expert Opin Ther Targets 10 689 701
23. McAuliffe JLA, Steinert D, Patel S, Benjamin R, Trent J. Kit-stem cell factor (Kit ligand) axis in GIST patients treated with imatinib. American Society of Clinical Oncology Annual Meeting, Edition Chicago, IL, USA; 2007.
24. H Sihto O Tynninen R Bèutzow 2007 Endothelial cell KIT expression in human tumours J Pathol 211 481 8
25. G Bergers S Song N Meyer-Morse 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.[see comment] J Clin Invest 111 1287 95
26. Dematteo ROK, Maki R, Pisters P, Blackstein M, Antonescu C, Blanke C, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrintestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. American Society of Clinical Oncology Annual Meeting, Edition Chicago, IL, USA; 2007.
27. RH Andtbacka CS Ng CL Scaife 2007 Surgical resection of gastrointestinal stromal tumors after treatment with imatinib Ann Surg Oncol 14 14 24
28. JY Blay A Le Cesne I Ray-Coquard 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25 1107 13
29. BL Eisenberg 2006 Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials Clin Colorect Cancer 6 S24 9
30. H Joensuu PJ Roberts M Sarlomo-Rikala 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 6